F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented tricyclic compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors and thus reported to be useful for the treatment of gram-negative bacterial infections.